Ensinger H, Majewski H, Hedler L, Starke K
J Pharmacol Exp Ther. 1985 Sep;234(3):681-90.
We have studied the contribution of neuronal and postjunctional dopamine (DA) receptors and of the DA1 and DA2 receptor subtypes to the blood pressure effects of DA and bromocriptine in the rabbit. The norepinephrine release rate, i.e., the rate of entry of endogenous norepinephrine into the plasma, was derived from the plasma level of endogenous norepinephrine and the plasma [3H]norepinephrine clearance. Bromocriptine (40 micrograms kg-1) lowered the norepinephrine release rate and the arterial blood pressure both in anesthetized rabbits and in pithed rabbits with electrically stimulated sympathetic outflow. These effects were antagonized by the selective DA2 antagonist domperidone but not by the selective DA1 antagonist SCH 23390. DA (10-160 micrograms kg-1 min-1) dose-dependently increased the norepinephrine release rate and caused only transient hypotension in anesthetized rabbits. However, after treatment with desipramine, DA did not change the norepinephrine release rate and produced a persistent fall in blood pressure. When DA and domperidone were given simultaneously to desipramine-treated rabbits, the hypotensive effect of DA was unchanged, but now DA increased the norepinephrine release rate. When DA and SCH 23390 were given simultaneously to desipramine-treated rabbits, DA failed to lower blood pressure and decreased the norepinephrine release rate. Propranolol did not change the effects of DA in desipramine-treated rabbits. These results suggest that bromocriptine decreases blood pressure by activating ganglionic and/or prejunctional, inhibitory DA2 receptors in the peripheral sympathetic nervous system. DA also activates these receptors, but in addition releases norepinephrine in the manner of an indirectly acting sympathomimetic amine and activates postjunctional vascular DA1 receptors, and the latter seems to be the main component in DA-induced hypotension.
我们研究了神经元和突触后多巴胺(DA)受体以及DA1和DA2受体亚型对兔体内DA和溴隐亭血压效应的作用。去甲肾上腺素释放率,即内源性去甲肾上腺素进入血浆的速率,由内源性去甲肾上腺素的血浆水平和血浆[3H]去甲肾上腺素清除率得出。溴隐亭(40微克/千克)降低了麻醉兔和电刺激交感神经传出的脊髓麻醉兔的去甲肾上腺素释放率和动脉血压。这些效应被选择性DA2拮抗剂多潘立酮拮抗,但未被选择性DA1拮抗剂SCH 23390拮抗。DA(10 - 160微克/千克·分钟)剂量依赖性地增加麻醉兔的去甲肾上腺素释放率,并仅引起短暂性低血压。然而,在用去甲丙咪嗪治疗后,DA未改变去甲肾上腺素释放率,并导致血压持续下降。当同时给去甲丙咪嗪治疗的兔注射DA和多潘立酮时,DA的降压作用未改变,但此时DA增加了去甲肾上腺素释放率。当同时给去甲丙咪嗪治疗的兔注射DA和SCH 23390时,DA未能降低血压并降低了去甲肾上腺素释放率。普萘洛尔未改变去甲丙咪嗪治疗兔中DA的作用。这些结果表明,溴隐亭通过激活外周交感神经系统中的神经节和/或节前抑制性DA2受体来降低血压。DA也激活这些受体,但此外还以间接作用拟交感胺的方式释放去甲肾上腺素,并激活突触后血管DA1受体,而后者似乎是DA诱导低血压的主要成分。